Speratum Biopharma is comprised of a team of talented scientists, clinicians, and executives committed to developing breakthrough science from bench to bedside.
Founder and Chief Executive Officer
Co-inventor of Speratum’s technologies
Chief Science Officer
Co-inventor of Speratum’s technologies
Founder and Managing
Director Carao Ventures
Speratum Biopharma, Inc. is an innovative biotechnology company focused on pre-clinical research and development of oligonucleotide therapeutics for the treatment of cancer. The company’s primary focus is developing a multi-component therapeutic against multiple cancer types that includes a proprietary RNA interference (RNAi)-inducing mimic of miR-198, a naturally occurring microRNA involved in the pathogenesis of several solid cancers, combined with a novel biocompatible material suitable for systemic and targeted delivery of nucleic acids.